Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest announcement is out from YD Bio Limited ( (YDES) ).
On April 30, 2026, YD Bio Limited reported its full-year 2025 results, highlighting a 17% rise in net revenue to about $597,000, driven by higher pharmaceutical sales such as Keytruda and new product launches, alongside a shift away from higher-priced medical products. However, the pivot toward lower-margin drugs, sharply higher operating expenses tied to expansion, R&D licensing and staff growth, and costs related to its August 2025 SPAC merger and PIPE financing widened the net loss to $8.3 million, even as the company ended 2025 with $6 million in cash and moved key ophthalmology and cancer-detection programs toward U.S. FDA submissions and broader commercial rollout.
Management framed 2025 as a transformative year in which the Breeze Holdings business combination and $13.2 million PIPE strengthened the balance sheet and funded stepped-up R&D, including securing patents and know-how and building an EG Telehealth Platform launched in March 2026. YD Bio also advanced its Limbal Stem Cell and exosome-based ophthalmic therapies through CMC completion and Drug Master Files, prepared for IND filings in dry eye disease and age-related macular degeneration, progressed its OkaiDx pancreatic cancer early detection program toward an FDA Q-Submission, and pursued a merger with EG BioMed to integrate DNA methylation AI, positioning the company as an emerging multi-vertical healthcare platform despite current losses.
Spark’s Take on YDES Stock
According to Spark, TipRanks’ AI Analyst, YDES is a Neutral.
The score is driven primarily by weak financial performance (losses, negative margins, and negative operating/free cash flow), partially offset by low balance-sheet leverage. Technical indicators add downside pressure with the price below key moving averages and a negative MACD, while valuation provides limited support due to loss-making earnings and no dividend.
To see Spark’s full report on YDES stock, click here.
More about YD Bio Limited
YD Bio Limited is a Taiwan-based biotechnology company listed on Nasdaq that focuses on DNA methylation-based cancer detection technologies and ophthalmologic innovations. The company combines diagnostics platforms, clinical service infrastructure and healthcare commercialization capabilities, targeting multiple regulated healthcare segments, including oncology screening, therapeutics and telehealth-enabled diagnostic services.
Average Trading Volume: 23,636
Technical Sentiment Signal: Buy
Current Market Cap: $359.7M
See more data about YDES stock on TipRanks’ Stock Analysis page.